MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
1.050
-0.010
-0.94%
Opening 15:24 11/10 EST
OPEN
1.060
PREV CLOSE
1.060
HIGH
1.090
LOW
1.020
VOLUME
61.23K
TURNOVER
--
52 WEEK HIGH
7.54
52 WEEK LOW
0.9457
MARKET CAP
5.84M
P/E (TTM)
-0.3386
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACXP last week (1102-1106)?
Weekly Report · 1d ago
Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television
Barchart · 3d ago
Acurx Pharmaceuticals, Inc. Amends Bylaws to Reduce Stockholder Quorum to 33⅓%
NASDAQ · 11/03 02:18
Weekly Report: what happened at ACXP last week (1026-1030)?
Weekly Report · 11/02 10:17
From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television
Barchart · 10/31 10:00
Acurx Pharmaceuticals Lowers Quorum for Shareholder Meetings
TipRanks · 10/29 21:49
Press Release: Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
Dow Jones · 10/26 12:01
Weekly Report: what happened at ACXP last week (1019-1023)?
Weekly Report · 10/26 10:17
More
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Webull offers Acurx Pharmaceuticals Inc stock information, including NASDAQ: ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.